The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. by Symonds, R. P. et al.
British Journal of Cancer (1996) 74, 312-317
©g3 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
The reduction ofradiation mucositis by selective decontamination antibiotic
pastilles: a placebo-controlled double-blind trial
RP Symonds', P Mcllroy', J Khorramil, J Paul', E Pyperl, SR Alcock2, I McCallum2,
ABJ Speekenbrink2, A McMurray3, E Lindemann3 and M Thomas4
'Beatson Oncology Centre, 2Department ofClinical Microbiology, 3Pharmacy, Western Infirmary, Glasgow GIl 6NT; 4Royal Naval
Hospital, Haslar, Gosport P012 2AA, UK.
Summary The aim of this study was to see if antibiotic pastilles could reduce radiation mucositis, pain,
dysphagia and weight loss in patients undergoing radical radiotherapy for head and neck cancer. A total of275
patients with T -T4 tumours entered the study; 136 were allocated to suck four times daily a pastille
containing amphotericin, polymyxin and tobramycin. The remaining 139 patients received an identical placebo.
In all, 54 patients were unevaluable (24 active, 30 placebo). Bacteriological monitoring was carried out before
and twice weekly during treatment. Both arms of the study were well balanced for T and N stage, age, sex and
radiation dose (60 Gy). There was a slight imbalance in the site of disease which had no substantive effect on
the results. The primary study end point was the percentage of patients who developed intermediate or thick
pseudomembranes. No statistically significant difference was found in this end point, with 36% of patients in
the active arm developing this type of membrane compared with 48% in the placebo arm (P=0.118). The
estimated odds ratio (placebo/active) of developing an intermediate or thick pseudomembrane was 1.59 (95%
CI 0.89-2.82). However a more sensitive test comparing the worst recorded mucositis grade between the two
arms was statistically significant (P=0.009). This indicated that the active pastilles had a beneficial effect, but
the magnitude was probably smaller than the trial was designed to detect. There was a reduction in mucositis
distribution (P=0.002), mucositis area (P=0.028), dysphagia (P=0.006) and weight loss (P=0.009) in the
active arm. There was a clear tendency for patients with positive cultures for aerobic Gram-negative bacteria
(AGNB) (P =0.003) and yeasts (P =0.026) during treatment to have more severe mucositis. The active pastilles
reduced the percentage of patients with yeast cultures (P =0.003) but had less effect on AGNB. The benefit
derived from the pastilles should materially increase patient tolerance to radical radiotherapy for head and neck
cancer.
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Mucositis following therapeutic irradiation of patients
suffering from head and neck cancer is a reactive
inflammatory process within the normal tissues of the upper
airways or upper digestive tract. Severe mucositis can
produce pain, difficulty in eating, drinking and speech. The
patient may lose weight and the overall general condition can
deteriorate markedly. The severity of symptoms may force
the clinician to stop radiotherapy prematurely or give the
patient a rest from treatment. Both actions can lead to
tumour persistence.
During treatment, cells in the basal layers of the mucous
membranes within the irradiated volume are unable to
replace adequately cells lost through inactivation or
exfoliation. The resultant mucosal damage may then be
exacerbated by colonisation of the affected area by abnormal
microbial flora. Mucositis has a number of manifestations
that may be seen at different times depending on the volume
irradiated, the total dose and the fractionation schedule.
Initially, there may be a transient white discolouration,
followed by deepening erythema and later a white
pseudomembrane which may be patchy or confluent. The
most severe manifestation is ulceration of the mucosa.
In health, the very diverse oropharyngeal flora contains a
marked preponderance of anaerobic bacteria together with a
near universal presence of lesser numbers of viridans
streptococci and Neisseria species. Irradiation, local tumour
and surgery can all interfere with the mucosal defences
important for the maintenance of this ecological balance. In
consequence, there is frequent overgrowth of organisms
rarely seen in health and then only at low concentrations.
Overgrowth of yeasts and aerobic Gram-negative bacilli (in
particular Enterobacteriaceae, Pseudomonads and Acineto-
bacter) has attracted particular attention in the context of
irradiation mucositis (van Saene and Martin, 1990).
There are no established effective measures to prevent or
treat mucositis. Standard therapy is to maintain good oral
hygiene and prescribe analgesics if necessary. A small study
by Spijkervert et al. (1991) described a novel approach to this
problem. Lozenges containing polymyxin E, tobramycin and
amphotericin B were used to eradicate selectively aerobic
Gram-negative bacteria (AGNB) and yeasts from the
oropharynx while retaining the normal anaerobic and
aerobic flora. This selective decontamination regimen was
given to 15 patients with head and neck cancer treated by
radiotherapy. An excellent microbiological result was
obtained and mucositis was confined to erythema in all
patients. By contrast, matched historical controls treated with
a placebo or chlorhexidene showed an 80% incidence of more
severe mucositis with pseudomembrane formation.
The aim of the study was to use a placebo-controlled
double-blind trial to test the hypothesis that the more severe
forms of irradiation mucositis are associated with abnormal
carriage of AGNB and yeasts and that selective reduction of
these microbial populations with non-absorbable antibiotics
would reduce both the signs and symptoms of mucositis.
Materials and methods
Patients receiving potentially curative radiotherapy for T-4
head and neck cancer were entered into this trial. The study
was approved by the Western Infirmary ethics committee and
all patients gave written informed consent. Patients were
randomised to receive either a placebo or active pastilles
containing polymyxin E 2 mg, tobramycin 1.8 mg and
amphotericin B 10 mg. The active and placebo pastilles
were identical and neither the patients, clinicians, nurses nor
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microbiologists were aware who was taking antibiotics. One
pastille was sucked four times daily from the start of
radiotherapy and this was continued until the radiation
reaction had settled. Tests with normal volunteers showed
that the pastille lasted at least 15 min if sucked rather than
chewed. All patients were given identical advice about
cleaning teeth and urgent dental treatment was arranged if
necessary. Both arms of the study used a sodium bicarbonate
mouthwash at least four times daily.
At randomisation, patients were divided into three strata:
those treated with the Medical Research Council CHART
regimen; patients irradiated using conventional daily sche-
dules and those receiving post-operative radiotherapy (Table
I). The CHART regimen is a hyperfractionated accelerated
schedule of 36 fractions of 1.5 Gy given 6 h apart over 12
days to a total dose of 54 Gy. Patients treated with a
conventional five fractions a week schedule were given 60-
70 Gy in 5-7 weeks depending on the volume treated. The
post-operative group were given 60 Gy in 30 fractions usually
to large volumes of tissue.
The primary study end point was the percentage of
patients with intermediate/thick pseudomembrane formation.
This was compared between the two arms using a Mantel-
Haenszel test. The study was conducted in a sequential way
with the primary study end point being assessed a maximum
of five times after results became available for every 44
evaluable patients. A constant nominal level of significance
(P=0.0158) was used as the criteria for stopping the study
early (Pocock, 1977). The study design provides approxi-
mately an 80% chance of detecting a 20% difference in the
percentage of patients with intermediate/thick mucous
membrane (from 50% on placebo to 30% on active
pastilles). The final analysis of the primary end point was
adjusted for these interim analyses as described in Whitehead
and Brunier (1989). This study was not stopped early.
The other study end points (the worst symptoms/signs of
mucositis recorded over the assessment period) were
compared using the Wilcoxon rank sum test incorporating
the stratification information via the van Elteren procedure
(Lehman, 1975). Baseline characteristics were compared using
the Wilcoxon rank sum test (ordinal data) or Pearson's chi-
square test (nominal data).
Patients were assessed weekly and weighed on a Seca
model 944 electronic chair scale. Mucositis was graded by
both appearance and functional effects. The percentage area
of mucositis within the irradiated volume, the distribution
(patchy or confluent) and the type of membrane (none, thin
opalescent, intermediate or thick) were recorded weekly as
was the degree of mucosal erythema (none, slight, moderate
or severe). The degree of dehydration and radiation-induced
oedema (mild, slight, moderate) was also noted. Most
patients were examined by both an experienced consultant
radiation oncologist and a consultant ENT surgeon. The size
and location of the irradiated volume were known by the
observers. Patients were asked about pain on swallowing
(none, slight, moderate or severe) and severity of dysphagia
(none, some discomfort swallowing with no dietary
disturbance, difficulty swallowing requiring soft diet, con-
Table I Patient randomisation by treatment
Active Placebo
% No. % No. P-value
Type of surgery
Debulking 10 11 6 7 0.563
Definitive 21 24 19 21
None 69 77 74 81
Type of radiotherapy
CHART 13 14 16 17 0.508
Conventional 87 98 84 92
siderable difficulty taking mainly liquid diet, severe difficulty
requiring nasogastric tube or IV feeding). Patient compliance
and any other antibiotic or antifungal agent prescribed were
also recorded.
Patients were defined as evaluable if they had at least one
assessment of pseudomembrane formation in each of the
successive 2 week periods in the 8 weeks following the start of
radiotherapy. Fifty-four patients were unevaluable (24 taking
the active preparation, 30 the placebo). Only evaluable
patients were used in the analysis regardless of the patients
apparent compliance with the pastille regimen. The double-
blind nature of the study and the fact that the main reason
for a patient being unevaluable was the referring clinician
suggests that little or no bias has been introduced into the
treatment comparison by the exclusion of these patients from
the analysis.
Oropharnygeal bacterial flora were sampled twice before
radiotherapy and then twice weekly. Patients gargled for 30 s
with 10 ml of sterile saline, which was collected in a sterile
container then promptly transported to the laboratory. The
microbiological content was assessed using a quantitative
technique designed to allow optimum detection of low
concentrations of AGNB (Spijkervet et al., 1989a). Standard
microbiological methods were employed for organism
identification (Collee et al., 1989). Antibiotic sensitivities of
bacteria were determined with a standardised disc diffusion
technique.
Table n Patient pretreatment characteristics
Active Placebo
% No. % No. P-value
Site of primary
Oral cavity 17 19 22 25 0.044
Nasopharynx 6 7 1 1
Oropharynx 14 16 22 24
Hypopharynx 4 4 8 9
Larynx 51 57 37 41
Nasal sinuses 4 4 1 1
Parotid gland 3 3 1 1
Other 2 2 6 7
Histology
Squamous 94 105 92 100 0.565
Adenocarcinoma 3 3 3 3
Other/unknown 4 4 6 6
T-stage
1 21 23 17 18 0.258
2 45 50 39 42
3 16 18 24 26
4 17 19 17 19
Unknown 2 2 4 4
N-stage
0 76 85 70 76 0.294
1 7 8 7 8
2 8 9 12 13
3 9 10 11 12
M-stage 100 112 100 109 1.00
0
Sex
Female 23 26 31 34 0.182
Male 77 86 69 75
Age (years)
Median 62 61 0.842
IQ range 54-69 55-67
Range 20-83 22-82
Total dose tumour (Gy)
Median 60 60 0.341
IQ range 60-64 60-66
Range 40-70 40-68
__
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Results
Both arms of the study are well balanced after randomisation
for age, sex, T and N stage, histology and total mean
radiation dose (Table II). Those with an unknown T stage
were patients with lymph node metastasis from an
undiscovered primary head and neck cancer. There was a
slight imbalance between the two arms in terms of site of
primary disease. This is due to the fact that most
nasopharynx patients had the active pastilles. If the analysis
is repeated omitting this site, the same end points have
statistically significant differences, although in general the
level of significance is reduced.
Over the eight assessment weeks patients were asked
whether or not they were still taking the pastilles. As a
measure of compliance the percentage of weeks assessed
where the patient responded 'yes' to this question was
calculated. These data are summarised in Table III and
shows that compliance was good.
In this randomised double-blind trial the antibiotic-
containing pastilles had a beneficial effect both on observed
differences in appearance, in the degree of mucositis and also
the functional consequences (Table IV). The primary study
Table m Patient compliance
Assessed weeks where
patient says that they
are still taking pastilles Active Placebo
(%) % No. % No.
100 85 95 76 83
75-99 5 6 14 15
<75 10 11 10 11
Table IV Mucositis signs by type of pastille (worst record over
assessment period)
Active Placebo
% No. % No. P-value
Type of membrane
None/thin 64 72 52 57 0.12
Intermediate/thick 36 40 48 52
Type of membrane
None 24 27 11 12 0.009
Thin 40 45 41 45
Intermediate 33 37 39 42
Thick 3 3 9 10
Erythema of mucosa
Nil 0 0 1 1 0.060
Slight 33 37 24 26
Moderate 61 68 62 68
Severe 5 6 13 14
Mucositis distribution
None 24 27 11 12 0.002
Patchy 62 69 61 67
Confluent 14 16 27 30
Degree of dehydration
Nil 95 105 96 102 0.681
Slight 5 5 3 3
Moderate 0 0 1 1
Oedema
Nil 56 62 43 46 0.174
Slight 32 35 44 47
Moderate 12 13 12 13
Mucositis area
Median 30 40 0.028
IQ range 5-60 15-70
Range 0-100 0 100
end point was the percentage of patients who developed
intermediate or thick pseudomembranes. No statistically
significant difference was found in this end point, with 36%
of patients in the active arm developing this type of
membrane compared with 48% in the placebo arm
(P=0.118). The estimated odds ratio of developing inter-
mediate/thick pseudomembrane (placebo/active) was 1.59
(95% confidence interval 0.89-2.82). However, a more
sensitive test comparing the worst recorded grades between
the two arms was statistically significant (P=0.009).
Differences in mucositis distribution (P=0.002) and area of
irradiated mucosa showing mucositis (P=0.028) were also
significant. This indicates that the active pastilles do have a
beneficial effect but the magnitude of this is probably smaller
than the trial was designed to detect. There was a non-
significant trend for patients taking the active pastilles to
have less mucosal erythema (P=0.061). The incidence of
radiation-induced oedema was not significantly different in
either arm (P=0.166).
The functional consequences of mucositis were signifi-
cantly reduced in the active arm, severity of dysphagia
(P=0.006), and especially the highly objective end point,
percentage weight loss (P=0.009) (Table V). The reduction in
pain was just short of statistical significance (P=0.056).
Figure 1 shows the number of patients whose mouth
washings yielded yeast isolates in each of the weeks after
Table V Mucositis symptoms by type of pastille (worst recorded
over assessment period)
Active Placebo
% No. % No. P-value
Pain on swallowing
None 13 14 10 11 0.056
Slight 55 62 40 44
Moderate 23 26 38 41
Severe 9 10 12 13
Severity of dysphagia
None 8 9 4 4 0.006
Some discomfort 30 34 17 19
Difficulty swallowing 44 50 55 60
Considerable difficulty 17 19 18 20
Severe difficulty 0 0 2 2
Nasogastric tube 0 0 4 4
Percentage weight loss (kg)
Median 3.3 5.1 0.009
IQ range 1.4-5.5 2.0-8.5
Range 0.0- 14.9 0.0-17.06
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starting pastille treatment. The treatment group showed a
striking and statistically significant reduction in the number
of yeast-positive patients for all of the weeks studied. A
separate analysis (Table VI) confirmed that the pastilles
significantly (P=0.003) reduced the percentage of patients
with one or more yeast isolates during treatment and that this
result was unaffected by the presence or absence of yeasts in
pretreatment cultures.
In contrast, the active pastilles failed to reduce the
percentage of patients with AGNB cultured during treat-
ment (P=0.256), irrespective ofwhether or not these bacteria
were cultured before treatment (Table VII). There was a
consistent reduction in the proportion of treated patients
whose mouth washings yielded AGNB in any one week
(Figure 2), but this effect was only seen from week 3 of
treatment and reached statistical significance in only 3 of the
7 weeks affected.
The mouth washings yielded a wide range of AGNB
species, with a preponderance of coliform strains (Table
VIII). Isolates from the pastille and placebo groups showed
no significant difference in the distribution of AGNB species.
The relationship of the microbiological results to
Table VI Percentage of patients with yeast present during radio-
therapy
Patients with yeast present during
XRT (%)
Active Placebo
Yeast present before XRT?
No (n= 159) 30 51
Yes (n= 30) 70 90
(P=0.003).
Table VII Percentage of patients with AGNB present during
radiotherapy
Active Placebo
AGNB present before XRT?
No (n=131) 46 58
Yes (n=58) 85 84
(P=0.256).
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Figure 2 Aerobic Gram-negative bacilli isolates during and after
radiotherapy.
pseudomembrane formation is of particular interest because
pseudomembranes are generally accepted as an index of
severe mucositis. Table IX shows that patients who had thick
or intermediate pseudomembrane formation during treatment
were significantly more likely to have shown cultures positive
for AGNB (P=0.003). A similar, but less striking relation-
ship (Table X) was seen with yeasts (P=0.026).
Given the very marked effect of active pastilles on yeast
isolates, it might be expected that the relationship of severe
mucositis with yeast presence would be weaker in patients
receiving active pastilles. (Table XI) confirms that this was
indeed the case: for active pastilles there was very little
difference in the percentage of patients with intermediate/
thick pseudomembranes according to the presence or absence
of yeasts (32% vs 36%) whereas for the placebo group this
difference was large (38% vs 52%).
There was no significant association between treatment
group and the incidence of resistance among AGNB to the
pastille drugs, and this finding was not affected by the
detection of resistant AGNB strains in pretreatment samples.
However, following the onset of treatment, a significant
minority (13%) of all pastille patients showed at least one
isolate of a resistant strain (mainly Proteus or Serratia species
resistant to polymyxin). Outgrowth of resistant Gram-
positive organisms (including enterococci) was not seen and
there were no clinical problems associated with antibiotic
resistance.
For both active and placebo pastilles, patient groups with
higher treatment compliance had about a 25% smaller
incidence of patients with positive yeast cultures. In
contrast, compliance had no significant effect on the
isolation of AGNB (Table XII). The reduced isolation of
yeasts in the placebo group is at first sight surprising.
However, it is likely that patients who used the pastilles as
prescribed were also conscientious in following advice about
oral hygiene and these procedures may have affected the oral
flora as revealed in the mouthwash samples. The absence of a
compliance effect on AGNB, together with the disappointing
effect of active-pastilles against these organisms, suggests that
reduction of oral microbial populations by whatever means
may be more difficult with AGNB than with yeasts.
Table VIII Oral carriage of AGNB
Number ofpatientsa
Active Placebo
Escherichia coli 38 28
Enterobacter species 38 20
Klebsiella species 29 26
Proteus species 7 12
Pseudomonas species 17 17
Other AGNBb 27 35
aNumber ofpatients from whom an organism was isolated in any of
the samples taken. bAcinetobacter, Citrobacter, Hafnia, Serratia and
unidentified species of aerobic Gram-negative bacilli.
Table IX Association between AGNB cultures and degree of
mucositis
AGNB present during treatment?
No (n= 72) Yes (n= 117)
Type of membrane
None 26 15
Thin 46 39
Intermediate 26 40
Thick 1 7
(P=0.003).Reduction of radiadon mucositis by antibiotic pastilles
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Table X Association between yeast cultures during treatment and
degree of mucositis
Yeasts present during treatment?
No (n =102) Yes (n =87)
Type of membrane 25% 13%
None 41% 41%
Thin 31% 39%
Intermediate 3% 7%
Thick
(P=0.026).
Table XI Association between mucositis and yeasts by type of
pastille (active or placebo)
Active pastilles Placebo pastilles
Yeast present during Yeast present during
treatment? treatment?
No Yes No Yes
(n =65) (n =33) (n =37) (n =54)
Type of membrane
None 28% 18% 19% 9%
Thin 40% 45% 45% 39%
Intermediate 29% 36% 35% 41%
Thick 3% 0% 3% 11%
Table XII Effect of compliance upon yeast and AGNB cultures
during radiotherapy
Active pastilles Placebo pastilles
Compliance Compliance
<80% >80% <80% >80%
(n =8) (n=90) (n= 10) (n=81)
Yeast present during 75% 30% 70% 59%
treatment
AGNB present during 50% 60% 60% 65%
treatment
Discussion
Therapeutic radiation dosage is usually limited to levels
where the risks of late damage are small. The severity of
symptoms caused by acute mucositis may limit the radiation
dose given and compromise the chance of cure. There is a
steep dose-response curve for most head and neck cancers
(Shukowsky and Fletcher, 1973). To obtain optimum results
treatment must be given close to normal tissue tolerance. A
rest during treatment of 2-3 weeks certainly reduces acute
mucosal side-effects, but cure rates are also substantially
reduced (Amdur et al., 1989). More severe forms of mucositis
seem to develop in certain groups of patients. These include
those treated after surgery or receiving accelerated forms of
radiotherapy. After surgery, there may be impaired motility
of normal structures and grafts may still be healing with
areas of necrotic tissue which may be colonised by abnormal
microbial flora. Radiotherapy fields tend to be large and
include one or more parotid glands leading to reduction in
saliva production. Saliva washes away intraoral debris, food
particles and bacteria and contains immunoglobin A, all
factors important in the maintenance of normal mucosal
flora.
There is no standard therapy to prevent or treat radiation
mucositis. The use of the antiseptic mouthwash chlorhexidene
has been shown to be ineffective (Skijhervet et al., 1989b) or
even harmful (Foote et al., 1994). Soluble aspirin has been
popular for many years as a treatment for this condition but
it has never been tested in a randomised controlled trial. It is
possible that the anti-inflammatory properties of aspirin are
important along with its analgesic effects. Benzydamine, a
non-steroid anti-inflammatory agent with anaesthetic and
antimicrobial properties was tested in a double-blind placebo-
controlled trial containing 43 patients. The degree of
mucositis was statistically significantly reduced and there
was a non-significant trend in the reduction of radiation-
induced symptoms in favour of the active arm (Epstein et al.,
1989). Other agents, in particular sucralfate, a coating agent
which binds to ulcerated areas, have shown promise in small
uncontrolled studies but have not been found to be effective
when assessed more rigorously (Epstein and Wong, 1994).
This large, randomised, placebo-controlled, double-blind
trial shows significant, beneficial effects of a selective
decontamination regimen applied to the buccal mucosa and
oropharynx. There was a reduction in mucositis distribution
(P=0.002), mucositis area (P=0.028), dysphagia (P=0.006)
and especially weight loss (P=0.009) which is a highly
objective end point. These results support the findings of a
small, uncontrolled study when 15 patients were given
lozenges containing the same antibiotics (Spijkervet et al.,
1991). However, our findings are less striking. In particular,
the formation of pseudomembranes was inhibited rather than
completely prevented as described by Spijkervet and
colleagues.
Pseudomembrane formation is important, both because it
is an index of severe mucositis and because it is the principal
feature that distinguishes irradiation mucositis from yeast
stomatitis. The latter is an acute infection of the buccal
mucosa characterised by burning, tenderness or dryness and
the presence of white patches or deep red erosions.
Pseudomembranes consist of extruded plasma and dead
cells and their formation probably results from the combined
effects of irradiation damage and abnormal microbial
colonisation of the damaged mucosa. Both yeasts and
AGNB have been implicated in the microbial component,
and it has been suggested that AGNB are the principal factor
(Spijkervet et al., 1991; Martin, 1993). The results of this
study strongly suggest that yeast colonisation is a major
factor in the pathogenesis ofthe condition. However, they are
also compatible with an important role for AGNB,
particularly in the formation of the more advanced grades
of pseudomembranes. More investigation is required to
elucidate the complex microbiological features of this
condition.
The significant clinical benefit demonstrated with pastille
use probably relates to effects on both yeast stomatitis and
irradiation mucositis. Any effects ofthe pastilles in preventing
yeast stomatitis can reasonably be ascribed to the amphoter-
icin B component of the formulation. However, the reduction
in pseudomembrane formation may reflect a complex
interaction between the marked antifungal effect of the
amphotericin B combined with the less striking effect shown
by the two antibacterial agents against AGNB.
The high proportion (76%) of patients in the active group
who suffered some form of pseudomembrane formation may
have resulted from the limited ability of the pastille regimen
to reduce oral mucosal populations of AGNB. This
disappointing microbiological result contrasts strongly with
the use of the same antibacterials applied as a gel or paste to
the buccal mucosa in intensive care patients, when AGNB
populations are drastically reduced within 3 -4 days
(Stoutenbeek et al., 1984; Ledingham et al., 1988). The
striking success of the latter regimens may well reflect
prolonged drug exposure of mucosal organisms resulting
from the adherent gel or paste preparations used. This
feature, combined with the partial success of pastilles in the
present study, suggests a need for new formulations to allow
protracted delivery of antimicrobials to the buccal mucosa of
ambulant patients.
In spite of these reservations, the present study has
demonstrated that the use of pastilles containing tobramy-
cin, polymyxin and amphotericin produced a reduction in
mucositis problems that should be of sufficient magnitude to
increase materially patient tolerance to radical radiotherapy
for head and neck cancer.ReducP o of raiato nucosits by attbiedc pastex
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